Institutional Investors Must Be Pleased After a 7.3% Gain Last Week That Adds to Standard BioTools Inc.'s (NASDAQ:LAB) One-year Returns
Standard BioTools Announces Conference Call and Webcast for Second Quarter 2024 Financial Results on July 31, 2024
Standard BioTools Shareholders Back Growth and Governance Plans
Standard BioTools Plans to Sell 105.1M Shares in Secondary Offering - Filing
TD Cowen Maintains Standard BioTools(LAB.US) With Buy Rating, Maintains Target Price $3.5
Express News | Standard BioTools Inc Files for Offering of up to 105.1 Mln Common Shares by the Selling Securityholders - SEC Filing
Standard BioTools(LAB.US) 10% Shareholder Buys US$260K in Common Stock
Express News | Standard BioTools Purchases The Carterra LSA-XT System; No Financial Terms Disclosed
Express News | Standard BioTools Purchases the Carterra® Lsa-Xt System to Accelerate Data Delivery and Provide Greater Validation to Somascan Customers
$1.5M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying
Standard BioTools(LAB.US) 10% Shareholder Buys US$1.54 Million in Common Stock
Standard BioTools to Participate in Upcoming Investor Conferences
$3.5M Bet On This Healthcare Stock? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying
Express News | Standard BioTools Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Standard BioTools(LAB.US) 10% Shareholder Buys US$3.46 Million in Common Stock
Standard BioTools Inc. (LAB) Q1 2024 Earnings Call Transcript
Standard BioTools | 10-Q: Quarterly report
Express News | Standard BioTools Reaffirms Guidance
Standard BioTools: Strategic Insights and Regulatory Updates
Standard BioTools Q1 2024 GAAP EPS $(0.27) Misses $(0.12) Estimate, Sales $45.540M Miss $46.006M Estimate